재발성 비소세포성 폐암환자의 Afatinib과 삼칠충초정 병용투여 경과관찰 1례
A Case of Patient with Recurring Non-Small Cell Lung Carcinoma Treated with Samchilchoongcho-Jung in Conjunction with Afatinib
2
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Objective: The purpose of this study is to report the case of a patient with recurring non-small cell lung carcinoma (NSCLC) taking Samchilchoongcho-Jung with Afatinib. Methods: An NSCLC patient diagnosed with multiple bone and pulmonary metastasis was taking Afatinib (20 mg/day) and suffering from stomatitis caused by the Afatinib. The patient was treated with Samchilchoongcho-Jung (1,500 mg/ day) for 3 months. The tumor size was measured with computed tomography, and laboratory findings, including tumor markers (CEA, Cyfra 21-1), were also followed up. Stomatitis was measured by a numeric rating scale, and adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0. Results: After combined treatment, stable disease was shown on computed tomography. The tumor marker levels of CEA and Cyfra 21-1 were decreased, and the stomatitis significantly improved. NCI-CTCAE 4.0 showed no adverse events. Conclusion: This case study suggests that Samchilchoongcho-Jung may have a synergic effect, in conjunction with Afatinib, on the treatment of patients with recurring NSCLC.
Abstract
Objective: The purpose of this study is to report the case of a patient with recurring non-small cell lung carcinoma (NSCLC) taking Samchilchoongcho-Jung with Afatinib. Methods: An NSCLC patient diagnosed with multiple bone and pulmonary metastasis was taking Afatinib (20 mg/day) and suffering from stomatitis caused by the Afatinib. The patient was treated with Samchilchoongcho-Jung (1,500 mg/ day) for 3 months. The tumor size was measured with computed tomography, and laboratory findings, including tumor markers (CEA, Cyfra 21-1), were also followed up. Stomatitis was measured by a numeric rating scale, and adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0. Results: After combined treatment, stable disease was shown on computed tomography. The tumor marker levels of CEA and Cyfra 21-1 were decreased, and the stomatitis significantly improved. NCI-CTCAE 4.0 showed no adverse events. Conclusion: This case study suggests that Samchilchoongcho-Jung may have a synergic effect, in conjunction with Afatinib, on the treatment of patients with recurring NSCLC.
참고문헌 (26)
- Siegel RL, "Cancer Statistics", CA Cancer J Clin, 67(1), pp.7~30 (2017)
- Miller KD, "Cancer treatment and survivorship statistics", CA Cancer J Clin, 66(4), pp.271~289 (2016)
- Boolell V, "The Evolution of Therapies in Non-Small Cell Lung Cancer", Cancers(Basel), 7(3), pp.1815~1846 (2015)
- Xu M, "The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer", Ann Transl Med, 3(7), pp.96~ (2015)
- Mitsudomi T, "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancerharbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial", Lancet Oncol, 11(2), pp.121~128 (2010)
- Rosell R, "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13(3), pp.239~246 (2012)
- Yang JC, "Afatinib versus cisplatin-based chemotherapy for EGFR mutationpositive lung adenocarcinoma(LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials", Lancet Oncol, 16(2), pp.141~151 (2015)
- Park SC, "Recent Experimental Tendency for Herbal Medicines Treating Lung Cancer in South Korea", J of Kor Traditional Oncology, 13(1), pp.43~54 (2008)
- 정홍매, "진행성 비소세포성 폐암환자에 대한 항암플러스의 치료효능: 연속증례보고", 대한한방내과학회지, 32(1), pp.113~120 (2011), 대한한방내과학회
- Kwon EM, "Two Cases of Non-small Cell Lung Cancer Patients Treated with Allergen Removed Rhus Verniciflua Stokes Based Traditional Korean Medicine and Chemotherapy", J of Kor Traditional Oncology, 14(1), pp.13~20 (2009)
- Li SG, "The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis", PLoS One, 8(2), pp.e57604~ (2013)
- Kang HJ, "Inhibitory effects of HangAmDan-B1(HAD-B1) on A549 lung cancer cell proliferation and tumor growth in a xenograft model", Academia Journal of Scientific Research, 4(7), pp.187~193 (2016)
- Chang SH, "Letter to Editor : Gamchosasim-tang, Sawi-tang and Giotrif Combination Therapy for Metastatic Non-Small-Cell Lung Adenocarcinoma ;A Regression Case", J of Kor Traditional Oncology, 20(2), pp.1~4 (2015)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: Revised RECIST guideline(version 1.1)", Eur J Cancer, 45(2), pp.228~247 (2009)
- "Common Terminology Criteria for Adverse Events(CTCAE) v.4.0" (2010)[URL]
- Annual report of cancer statistics in Korea in 2014, "Ministry of health & wellfare", ~ (2016)
- Li D, "BIBW2992, an irreversible EGFR", HER2 inhibitor highly effective in preclinicallung cancer models, 2008, pp.27(34), 4702~4711
- Soria JC, "Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung(LUX-Lung 8): an open-label randomised controlled phase 3 trial", Lancet Oncol, 16(8), pp.897~907 (2015)
- Park K, "Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial", Lancet Oncol, 17(5), pp.577~589 (2016)
- Lee CY, "Inhibition of human colorectal cancer metastasis by notoginsenoside R1, an important compound from Panax notoginseng", Oncol Rep, 37(1), pp.399~407 (2017)
- Chou PY, "Trilinolein inhibits proliferation of human non-small cell lung carcinoma A549 through the modulation of PI3K", Akt pathway, 2011, pp.39(4), 803~815
- Bizarro A, "Cordyceps militaris(L.) Link Fruiting Body Reduces the Growth of a Non-Small Cell Lung Cancer Cell Line by Increasing Cellular Levels of p53 and p21", Molecules, 20(8), pp.13927~13940 (2015)
- Yu X, "Cordycepin induces autophagy-mediated c-FLIPL degradation and leads to apoptosis in human non-small cell lung cancer cells", Oncotarget, 8(4), pp.6691~6699 (2017)
- Wang L, "Ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to γ-radiation by targeting the nuclear factor-κB pathway", Mol Med Rep, 12(1), pp.609~614 (2015)
- Khan MA, "Pharmacological evidences for cytotoxic and antitumor properties of Boswellic acids from Boswellia serrata", J Ethnopharmacol, 191, pp.315~323 (2016)
- Choi YJ, "Inhibition of cell motility and invasion by HangAmDan-B in NCI-H460human non-small cell lung cancer cells", Oncology Reports, 26(6), pp.1601~1609 (2011)